Mark E. Fitzgerald
Impact in
-
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- Chemical Synthesis and Analysis
- Ubiquitin and proteasome pathways
Papers in
-
- Synthetic Organic Chemistry Methods 3
- Synthesis and Catalytic Reactions 3
-
- Protein Degradation and Inhibitors 6
- Ubiquitin and proteasome pathways 6
- RNA modifications and cancer 2
- Co-authors
- Jeffrey D. Winkler (2 shared papers)Jeremy R. Duvall (4 shared papers)Thomas Haimowitz (1 shared paper)Carol A. Mulrooney (2 shared papers)Christopher G. Nasveschuk (3 shared papers)Andrew J. Phillips (3 shared papers)Lakshmi B. Akella (2 shared papers)Byung‐Chul Suh (2 shared papers)
- Journals
- SLAS DISCOVERY (1 paper)ACS Combinatorial Science (1 paper)RSC Medicinal Chemistry (1 paper)Science (1 paper)Journal of Medicinal Chemistry (1 paper)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Mark E. Fitzgerald
20 papers receiving 783 citations
Mark E. Fitzgerald's Hit Papers
Peers
Comparison fields: 5 of 66
- Molecular Biology 574
- Cancer Research 96
- Oncology 143
- Organic Chemistry 153
- Biotechnology 40
Countries citing papers authored by Mark E. Fitzgerald
This map shows the geographic impact of Mark E. Fitzgerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Fitzgerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Fitzgerald more than expected).
Fields of papers citing papers by Mark E. Fitzgerald
This network shows the impact of papers produced by Mark E. Fitzgerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Fitzgerald. The network helps show where Mark E. Fitzgerald may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Fitzgerald, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells Hit paper breakdown → | 2016 | 521 |
| 2 | 2021 | 43 | |
| 3 | 2011 | 43 | |
| 4 | 2012 | 34 | |
| 5 | 2014 | 30 | |
| 6 | 2014 | 29 | |
| 7 | 2013 | 21 | |
| 8 | 2010 | 20 | |
| 9 | 2017 | 17 | |
| 10 | 2016 | 16 | |
| 11 | 2021 | 13 | |
| 12 | 2021 | 11 | |
| 13 | 2009 | 8 | |
| 14 | 2024 | 6 | |
| 15 | 2009 | 6 | |
| 16 | 2024 | 5 | |
| 17 | 2025 | 3 | |
| 18 | 2025 | 1 | |
| 19 | 2025 | 1 | |
| 20 | 2015 | 1 |
About Mark E. Fitzgerald
Mark E. Fitzgerald is a scholar working on Organic Chemistry, Molecular Biology, Hematology, Chemical Health and Safety and Computational Theory and Mathematics, having authored 20 papers that have together received 829 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (6 papers), Ubiquitin and proteasome pathways (6 papers), Synthetic Organic Chemistry Methods (3 papers), Synthesis and Catalytic Reactions (3 papers), Multiple Myeloma Research and Treatments (3 papers), RNA modifications and cancer (2 papers), Malaria Research and Control (2 papers) and Computational Drug Discovery Methods (2 papers). The work is most often cited by research in Molecular Biology (574 citations), Cancer Research (96 citations), Oncology (143 citations), Organic Chemistry (153 citations) and Biotechnology (40 citations). Mark E. Fitzgerald has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Jeffrey D. Winkler, Jeremy R. Duvall, Thomas Haimowitz, Carol A. Mulrooney, Christopher G. Nasveschuk, Andrew J. Phillips, Lakshmi B. Akella, Byung‐Chul Suh, Lisa A. Marcaurelle and Stewart L. Fisher. Their work appears in journals such as SLAS DISCOVERY, ACS Combinatorial Science, RSC Medicinal Chemistry, Science and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.